We are live on ! Find out more
PIM

Ponoi II Management Portfolio holdings

AUM $38.3M
1-Year Est. Return 32.02%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
-32.02%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$67.5M
AUM Growth
-$55.9M
Cap. Flow
-$57.1M
Cap. Flow %
-84.54%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$53.2M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.85M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$27.3M 40.46%
1,298,908
– –
RVMD icon
2
Revolution Medicines
RVMD
$39.6B
$18.8M 27.92%
685,011
– –
NRIX icon
3
Nurix Therapeutics
NRIX
$2.4B
$16.8M 24.93%
561,574
-124,700
-18% -$3.85M
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$4.51M 6.69%
18,175
– –
CNST
5
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
– –
-1,574,229
Closed -$53.2M

Similar funds

FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
PSCM
Prince Street Capital Management New York $40.3M AUM 0.66% 1-Year Est. Return

Ponoi II Management's Q3 2021 Portfolio in Review

As of Q3 2021, Ponoi II Management held 5 positions worth $67.5M, down 45% from $123M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Ponoi II Management withdrew a net $57.1M in Q3 2021, closing 1 position and reducing 1 holding. Its most notable exit was Constellation Pharmaceuticals, Inc., an estimated $53.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Ponoi II Management's biggest Q3 2021 reduction was Nurix Therapeutics, cutting an estimated $3.85M.
  • Ponoi II Management fully exited Constellation Pharmaceuticals, Inc. in Q3 2021, selling an estimated $53.2M.
  • Ponoi II Management's ten largest holdings make up 100% of its $67.5M portfolio in Q3 2021.
  • Ponoi II Management opened 0 new positions and closed 1 in Q3 2021.
  • Ponoi II Management's portfolio value fell 45% quarter-over-quarter to $67.5M.

Based on Ponoi II Management's 13F filing for Q3 2021, filed 12 Nov 2021.